In multiple murine tumor models, treatment with the peritumoral administration of half-life-extended interleukin-10–Fc fusion protein promoted the expansion of terminally exhausted CD8+ TILs and promoted the effector function and enhancing oxidative phosphorylation in these exhausted T cells [185]. The gene discussed is CD8A; the disease is neoplasm.